Samsung Files Remicade Biosimilar In Europe
This article was originally published in PharmAsia News
Executive Summary
Following an approval filing for its Enbrel biosimilar candidate in the EU earlier this year, Samsung is now expanding its European biosimilar ambitions to Remicade.